Literature DB >> 1885728

Model of recurrent pulmonary aspergillosis in rats.

Y Niki1, E M Bernard, F F Edwards, H J Schmitt, B Yu, D Armstrong.   

Abstract

Male Sprague-Dawley rats were treated with cortisone acetate and fed a low-protein diet for 3 weeks. At the end of week 2, animals were infected intratracheally with 10(5) conidia of Aspergillus fumigatus H11-20. Despite discontinuation of steroids and the low-protein diet 1 week after the infection, 94% of controls died of invasive pulmonary aspergillosis within 3 weeks postinfection. When rats were treated with a single dose of 1.6 mg of aerosolized amphotericin B per kg of body weight 48 h prior to the infection, mortality was reduced to 11% within 3 weeks postinfection. Despite apparent good health and rapid weight gain, all survivors showed multiple lesions in histopathological sections of the lungs, and 10(3) to 10(4) CFU of aspergilli was recovered from cultures of their lungs. With discontinuation of immunosuppression, the infection was slowly cleared; however, when cortisone acetate was restarted during week 5, reactivation of progressive invasive pulmonary aspergillosis was observed. On the basis of these results, we conclude that a single low dose of aerosolized amphotericin B prophylaxis is effective in preventing an exogenous aspergillus infection of the lung. Additional therapy is needed to prevent recurrent infection caused by endogenous aspergilli when immunosuppression is resumed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885728      PMCID: PMC270108          DOI: 10.1128/jcm.29.7.1317-1322.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  The effect of cortisone and antibiotic agents on experimental pulmonary aspergillosis.

Authors:  H SIDRANSKY; L FRIEDMAN
Journal:  Am J Pathol       Date:  1959 Jan-Feb       Impact factor: 4.307

2.  Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits.

Authors:  B Dupont; M Huber; S J Kim; J E Bennett
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

Review 3.  Problems in management of opportunistic fungal diseases.

Authors:  D Armstrong
Journal:  Rev Infect Dis       Date:  1989 Nov-Dec

4.  Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model.

Authors:  T F Patterson; P Miniter; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

5.  Evaluation of a test to detect circulating Aspergillus fumigatus antigen in a survey of immunocompromised patients with proven or suspected invasive disease.

Authors:  E V Wilson; V M Hearn; D W Mackenzie
Journal:  J Med Vet Mycol       Date:  1987-12

6.  Studies on the pathogenesis of experimental pulmonary aspergillosis.

Authors:  S M Epstein; E Verney; T D Miale; H Sidransky
Journal:  Am J Pathol       Date:  1967-11       Impact factor: 4.307

7.  Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.

Authors:  T F Patterson; P Miniter; J Dijkstra; F C Szoka; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

Review 8.  New methods for delivery of antifungal agents.

Authors:  F Meunier
Journal:  Rev Infect Dis       Date:  1989 Nov-Dec

9.  Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis.

Authors:  H J Schmitt; E M Bernard; M Häuser; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

10.  Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice.

Authors:  D M Dixon; A Polak; T J Walsh
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

View more
  12 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

3.  The proteomic signature of Aspergillus fumigatus during early development.

Authors:  Steven E Cagas; Mohit Raja Jain; Hong Li; David S Perlin
Journal:  Mol Cell Proteomics       Date:  2011-08-08       Impact factor: 5.911

Review 4.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

5.  Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.

Authors:  H M Miyazaki; S Kohno; Y Miyazaki; K Mitsutake; K Tomono; M Kaku; H Koga; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 6.  Nebulized antibiotics in cystic fibrosis.

Authors:  Isabelle Sermet-Gaudelus; Yann Le Cocguic; Agnés Ferroni; Marlène Clairicia; Joel Barthe; Jan-Pierre Delaunay; Valentine Brousse; Gérard Lenoir
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 7.  Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis.

Authors:  J Beyer; S Schwartz; G Barzen; G Risse; K Dullenkopf; C Weyer; W Siegert
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

8.  Murine model of invasive pulmonary aspergillosis following an earlier stage, noninvasive Aspergillus infection.

Authors:  R Nawada; R Amitani; E Tanaka; A Niimi; K Suzuki; T Murayama; F Kuze
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

9.  A novel fungus concentration-dependent rat model for acute invasive fungal rhinosinusitis: an experimental study.

Authors:  Yuyan Yan; Zuotao Zhao; Hongfei Wan; Ruochen Wu; Jugao Fang; Honggang Liu
Journal:  BMC Infect Dis       Date:  2014-12-20       Impact factor: 3.090

10.  Emergence of Echinocandin Resistance Due to a Point Mutation in the fks1 Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis.

Authors:  Cristina Jiménez-Ortigosa; Caroline Moore; David W Denning; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.